Published on 10 Apr 2024 on Zacks via Yahoo Finance
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
Moderna MRNA shares ended the last trading session 6.2% higher at $111.60. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.2% loss over the past four weeks.
Shares price rose after management reported encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in certain patients with head and neck cancer.
This portion of the study evaluated the combination of mRNA-4157 and Merck’s blockbuster immuno-oncology drug Keytruda in patients with human papillomavirus negative (HPV-) head and neck squamous cell carcinoma (HNSCC).